Orange Book product · Brand (NDA)
AVOPEF
ETOPOSIDE
At a glance
Feb 13, 2026
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 13, 2026
4 mo ago
Today
Pharmaceutical detail
Active ingredient
ETOPOSIDE
Strength
100MG/5ML (20MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 220200
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 1986VEPESIDBrand (NDA)
NDA 019557 · ONESOURCE SPECIALTY
- 1983VEPESIDBrand (NDA)
NDA 018768 · CORDEN PHARMA
- 2017ETOPOSIDEGeneric (ANDA)
ANDA 203507 · NATCO PHARMA USA
- 2017ETOPOSIDEGeneric (ANDA)
ANDA 204927 · NATCO PHARMA USA
- 2001ETOPOSIDEGeneric (ANDA)
ANDA 075635 · MYLAN
- 1998ETOPOSIDEGeneric (ANDA)
ANDA 074983 · FRESENIUS KABI USA
- 1998ETOPOSIDEGeneric (ANDA)
ANDA 074968 · WATSON LABS INC
- 1997ETOPOSIDEGeneric (ANDA)
ANDA 074813 · PIERRE FABRE
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074228 · WATSON LABS
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074529 · MEITHEAL
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074513 · ACCORD HLTHCARE
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074227 · PHARMACHEMIE BV
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
